Combining kidney-sparing surgery with postoperative radiotherapy for advanced ureteral cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the safety and efficacy of kidney-sparing surgery combined with postoperative adjuvant radiotherapy in patients with high-risk locally advanced ureteral cancer. It will analyze outcomes compared to traditional radical surgery, focusing on preserving renal function while effectively treating the tumor. The study will utilize an ambispective approach, incorporating both retrospective and prospective data to assess patient outcomes and tolerability of subsequent therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- 1) Ureteral cancer patients with high-risk factors (high-risk factors define multifocal; G3; T2-4); surgery may be performed with patients undergoing partial terminal ureteral resection or radical nephroureterectomy 2)Age ≥18 years; 3)Completion of abdominopelvic CT 4 weeks before enrollment to exclude distant metastasis and regional lymph node metastasis.

4\) Patients did not have other malignant neoplastic diseases in the last 5 years except for non-melanoma of the skin and ductal carcinoma in situ of the breast; Willing to participate in perfecting the necessary examinations and follow-up for the sake of the study, and willing to provide written informed consent.

Exclusion Criteria:

* 1\) Distant metastasis or retroperitoneal lymph node metastasis (N+) had been detected at the time of surgery; R2 resection patients; history of bladder cancer; 2) History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy; 3) Pregnant women or breastfeeding women; or women of childbearing potential who are not practicing reliable contraception; (4) The presence of active infections in those with pre-existing or coexisting bleeding disorders 5) clinically significant cardiac disease (e.g., hypertension controlled with medications, unstable angina, New York Heart Association (NYHA) class ≥II congestive heart failure, unstable symptomatic arrhythmias, or class ≥II peripheral vascular disease); 6) Psychological, family, and social factors leading to lack of informed consent.

Where it's running

• Departmeng of Urology, Peking University First Hospital
  Beijing, China Recruiting
• Department of Radiotherapy Oncology, Peking University First Hospital
  Beijing, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• AVZO-103 alone and with other treatments for advanced urothelial and other solid tumors

  This trial will test intravenous AVZO-103, alone and combined with other cancer drugs, to see if it is safe and helps adults with locally advanced or metastatic urothelial cancer or other solid tumors.

  Recruiting at 15 sites Phase 1/2 Avenzo Therapeutics, Inc. · San Francisco, California and 14 other locations · NCT07193511

• CUE-101 with pembrolizumab for locally advanced HPV‑16 positive oropharyngeal cancer

  This trial tests whether CUE-101 alone or combined with pembrolizumab before definitive therapy helps people with newly diagnosed, locally advanced HPV‑16 positive oropharyngeal cancer who are HLA‑A*02:01 positive.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT07172256

• YntraDose™ given before chemotherapy for locally advanced, unresectable pancreatic cancer

  This will test whether a one-time, image-guided injection of YntraDose™ (Y-90 radioactive microspheres) into the pancreatic tumor, combined with standard chemotherapy, is safe and can help control locally advanced unresectable pancreatic cancer.

  Recruiting at 2 sites BetaGlue Therapeutics SpA · Roma and 1 other locations · NCT07155850

• AVZO-1418 alone and with other treatments for advanced epithelial solid tumors

  This trial will test whether intravenous AVZO-1418, alone or with other cancer drugs, is safe and helps adults with locally advanced or metastatic epithelial solid tumors, including some lung cancers.

  Recruiting at 27 sites Phase 1/2 Avenzo Therapeutics, Inc. · Gilbert, Arizona and 26 other locations · NCT07038343

• Digital symptom monitoring for people starting cabozantinib plus nivolumab for advanced clear-cell kidney cancer

  This project tests whether weekly digital self-reports of symptoms can help guide treatment management for adults beginning cabozantinib plus nivolumab for advanced clear-cell kidney cancer during the first three months.

  Recruiting at 3 sites Phase 4 Centre Francois Baclesse · Annecy and 18 other locations · NCT07028125

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.